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1. Introduction 
Average life expectancy in the world is getting longer in the developing countries as well as 
developed countries. This means that we will encounter some of the diseases more than 
diseases which are only seen in elderly, in the coming years. Dementia is one of the most 
important health problems of the elderly population today, up to the developed countries is 
seen as a major threat in developing countries. WHO projections suggest that by 2025, about 
three-quarters of the estimated 1·2 billion people aged 60 years and older will reside in 
developing countries (1). Thus, by 2040, if growth in the older population continues, 71% of 
81·1 million dementia cases will be in the developing world (Figure 1) (2). 
Epidemiology is the study of health-event patterns in a society (3). It is the cornerstone 
method of public health research, and helps inform evidence-based medicine for identifying 
risk factors for disease and determining optimal treatment approaches to clinical practice 
and for preventive medicine. Epidemiologic measures are named as two types; incidence 
and prevalence. Whereas incidence deals with what is new, prevalence deals with what 
exists. By definition, prevalence is the number of cases of a given disease that exists in a 
defined population at a specified time. Incidence represents new event.  
Dementia is actually a syndrome. It may be caused by various underlying diseases, each 
characterized by specific clinical features and neuropathology. Alzheimer disease (AD) which 
is a neurodegenerative is the most prevalent cause of dementia. The neuropathology of disease 
include in neuritic plaques and neurofibrillary tangle in the brain. Vascular dementia (VaD), 
describing impairments in cognitive function caused by problems in cerebral or cardiac blood 
vessels, is the second most common cause of dementia after Alzheimer disease in the aging 
population (Figure 2) (4). It comprises 10-20 % of all dementia. A meta-analysis of the 
European studies on incidence of dementia showed that VaD constitute 17.6 % of all dementia 
(5).  In Europe and North America, AD is more common than VaD in a 2:1 ratio; in contrast in 
Japan and China VaD accounts for almost 50 % of all dementia (6, 13).  
Vascular dementia is a complex disease and a common complication resulting from a 
blocked blood vessel causing a stroke. The most common mechanisms underlying VaD are 
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multiple large-vessel infarcts, a single strategically placed infarct (angular gyrus, thalamus, 
basal forebrain, posterior cerebral artery or anterior cerebral artery), multiple basal ganglia 
and white matter lacunes, or extensive periventricular white-matter lesions. The most 
commonly encountered subtype of VaD is extensive periventricular white-matter lesions. 
Multiple large vessel infarcts and others follow up them (14).  
 
Fig. 1. Dementia prevalence 2001, 2020, 2040 by WHO Region Source: Ferri et al. (2005).  
Vascular dementia is historically reflected by the diagnoses of “dementia with stroke” or 
“multi-infarct dementia,” although these terms have been replaced with the broader 
concepts of vascular dementia and vascular cognitive impairment, recognizing the 
contribution to dementia of all vascular disease. Pathological findings have shown that 
much dementia cannot be attributed to a single underlying cause but arises from a 
combination of factors among which cerebrovascular disease, including infarct and 
haemorrhage, is an important contributor. 
Although the incidence and prevalence of dementia are increasing, determining the 
incidence and prevalence of dementia is difficult (15-20).   
Even with the difficulties of detecting and defining to prevalence and incidence in the 
population, it is clear that dementia causes a substantial burden on societies. There is an 
urgent need to develop preventive strategies and to identify of modifiable risk factors about 
each type of dementia. Newer imaging techniques and neuropsychological test batteries 
provide an opportunity to identify subclinical manifestations of "dementias" that can be 
limited to the risk factors and subsequent clinical disease. Problems with diagnostic 
inaccuracy and insidious disease onset influence results of the epidemiologic studies (21).   
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Fig. 2. Prevalence of dementia subtypes Data from the Cambridge City Over-75s Cohort 
Study (CC75C). 
Epidemiologic studies of VaD have been also affected by variations in the definition of the 
disorders, the clinical criteria used and the methods. Analysis of data from 12 centres for 
which imaging findings were available indicates that 26% of cases of dementia fulfilled the US 
National Institute of Neurological Disorders and Stroke and Association Internationale pour la 
Recherché et l'Enseignement en Neurosciences (NINDS–AIREN) criteria for VaD (22,23).  
2. Prevalence and incidence 
Prevalence estimates vary highly between studies because of methodological and 
geographical differences (Table 1) (24). However, the prevalence of VaD ranges from one to 
four percent in people over the age of 65 and seems to be higher in China and Japan than in 
Europe and North America. While the rate is 1.5% in Western countries and in Japan is 
approximately 2.2%. In Japan, vascular dementia accounts for 50% of all dementias that 
occur in individuals older than 65 years. In Europe, vascular dementia and mixed dementia 
account for approximately 20% and 40% of cases, respectively (25-28).  
In 2000, prevalence data from 11 European population based studies were pooled to obtain 
stable estimates of prevalence of dementia in the elderly (>65 years). Age standardised 
prevalence was 6.4% for dementia (all causes), and 1.6% for VaD (29).  In clinical studies, the 
prevalence of VaD ranges from 4.4% and 39%, its incidence from 0.42 to 2.65, with doubling 
every 5 years in western memory clinical and population based series. In Asia, a number of 
studies on the prevalence of dementia have been published in Chinese, yielding varied 
results. By comparison with these studies that reported a prevalence range of VaD as 0.2 % 
to 2.7 %, respectively for those aged 60 years and older (30). 
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Data suggests that the annual incidence of VaD may range from 20-40 per 100000 between 
persons 60-69 years old to 200-700 per 100.000 in persons over age 80.  
 
Table; Brayne C, Cambridge City Over-75s Cohort Cc75c Study Neuropathology Collaboration. 
Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based 
Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis. 2009 ( The Turkish data was added). 
Table 1. 
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3. Age and gender 
Studies show that the occurrence of VaD exponentially increases with age from 65 to 85 
years. The prevalence of dementia of all causes increases between the seventh and tenth 
decade from 0.8 to 28.5% that of vascular dementia (VD) (15.8% of total) from 0.3 to 5.2% or 
from 0.2 to 16% over age 80.  In 2030, nearly 70 million patients with dementia is expected in 
65 and older populations, without any substantial difference between men and women. 
Under eighty-five years of age the prevalence of VaD was higher in men compared to 
women and thereafter the prevalence was higher in women (29). In a longitudinal 
community survey of Japanese American men (Honolulu Asia Aging Study), 23% of 
vascular dementia was attributed. to large-vessel, 50% to small-vessel, and 16% to mixed-
vessel disease (31).   
The age-standardized prevalence of VaD was 1.6% and also increased with age. However, 
contrary to AD, the difference in prevalence between men and women was age dependent. 
This finding might also be attributed to differences in survival between men and women. 
However, it may also reflect changes in incidence pattern. 
4. Variation across region 
There are differences amongst cultural, demographic and ethnic variability in incidence and 
prevalence studies.  The proportion of AD and VaD dementia was different from that in 
Europe and other Asian countries. For example, VD tends to be more common than AD in 
Japan and Russia (31-32). Even, a marked geographical dissociation in Europe between the 
north and south, linked to differences in vascular risk factors has been proposed to account 
for the higher incidence rates in the oldest-old of north-western countries (Finland, Sweden, 
Denmark, the Netherlands, and the United Kingdom) compared to southern countries 
(France and Spain). This difference is further supported by north–South regional findings of 
differences in MRI-detected white matter lesion (WML) pathology. Greater WML pathology 
linked to progression of dementia has been observed in southern Europe relative to 
northern and central European countries (33,35).   
Few studies reported the differences in the distribution of dementia subtypes between rural 
and urban areas. Interestingly, they found that there was a significantly higher prevalence of 
Alzheimer disease in the rural area than the urban area. And on the contrary, there was a 
higher prevalence of vascular dementia in the urban area than the rural area.  It may be 
owing to the differences in education levels, socioeconomic status, obesity and body mass 
index, diet, and life style between the two areas. If the future studies continue to report the 
higher prevalence of vascular dementia in urban areas, it means that there will be increased 
demands on healthcare system particularly among urban populations (36-40).  
5. Family history and genetic 
Dementia risk can increase two- to four-fold among individuals who have at least one first 
degree relative with dementia.  Genetic factors play an important role in the aetiology of 
VaD. However, there is less epidemiological evidence for a genetic component of risk factors 
of VaD like cardio embolic stroke. Two known genetic disease can be thought that VaD have 
genetic characteristics. These are cerebral autosomal dominant arteriopathy with subcortical 
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infarcts and leucoencephalopathy (CADASIL: a subcortical small vessel disease 
accompanied by lacunars’ strokes, migraine, and dementia) and hereditary cerebral 
haemorrhage with amyloidosis- Dutch type (HCHWA-D) (41).  
The CADASIL condition is a heritable small-vessel disease caused by mutations in NOTCH3 
gene which is normally expressed in vascular smooth muscle cells and pericytes (including 
those of the cerebral vasculature) and that encodes a cell-surface receptor, which has a role 
in arterial development and is expressed on vascular smooth-muscle cells.  About 95% of 
patients have missense mutations that cluster in exons 3, but the pathogenic mechanism is 
still unknown. With regard to HCHWA-D (a syndrome of primarily hemorrhagic strokes 
and dementia), it is caused by a mutation in the gene for amyloid precursor protein (APP) 
that causes abnormal deposition of amyloid in the walls of leptomeningeal arteries and 
cortical arterioles, it is  known as cerebral amyloid angiopathy [CAA] (42).  
The studies using the candidate gene approaches has identified a number of genetic variants 
possibly involved in risk factor development. They can contribute to conventional risk 
factors such as hypertension, diabetes, or homocysteine concentrations. Recently, APO E4 
was studied in VaD after AD as risk factors.  As authors, VaD risk also increases with the 
number of alleles: homozygous carriers are at a greater risk than heterozygous carries or 
those who do not carry the E4 variant (43, 44).  
A study showed that MAPT (microtubule-associated protein tau) was associated with VaD 
and since MAPT is a gene playing an important role in AD. Moreover, G allele of rs1467967 
is the risk allele, which is the major allele in Chinese population (45). 
6. Hypertention and other vascular risk factors 
Mid-life hypertension (high blood pressure) has been associated with impaired cognitive 
function even in otherwise healthy individuals (46). Traditionally VaD has been considered 
affected by hypertension and the alleviation of it. In a Japan study, the age- and sex-adjusted 
incidence of VaD significantly increased with elevated late-life blood pressure levels 
whereas no such association was observed for Alzheimer disease. The current meta-analysis 
highlights the potential importance of rigorous treatment of hypertension as a key measure 
to help prevent the development of VaD (47).   
Except hypertension, histories of diabetes, metabolic syndrome, hyperlipidemia, myocardial 
infarction/cardiac decomposition, heavy smoking, obesity and a history of stroke are other 
risk factors for VaD. The Cardiovascular Health Cognition Study developed a late-life 
dementia risk index that included older age, worse cognitive test performance, lower body 
mass index (BMI), APOE _4 allele, MRI findings of white matter disease or ventricular 
enlargement, internal carotid artery thickening on ultrasound, history of bypass surgery, 
slower physical performance, and lack of alcohol consumption (48).  
7. Lifestyle  
Risk finding for alcohol is not consistent. Alcohol has been found to have a protective effect 
in moderate drinkers with a five-fold increase in dementia in both abstainers and those who 
drink heavily. A study found a link between increasing alcohol consumption and VaD (49). 
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In some studies alcohol and smoking are neither strongly protective nor predictive (50).  In 
some studies were informed that high educational attainment, eating fish or shellfish, physical 
exercise, use of supplementary antioxidants like beta-carotene, omega-3, Vitamins E and C, 
use of Vitamin B12, Mediterranean diet might be potential protective factors for VaD (51,53). 
8. Conclusion remarks 
1. Vascular dementia (VaD) is the second most common cause of dementia after 
Alzheimer disease in the aging population. 
2. Prevalence estimates vary highly between studies because of methodological and 
geographical differences. 
3. Prevalence rate is 1.5% in Western countries and in Japan is approximately 2.2%.  
4. Annual incidence of VaD may range from 20-40 per 100000 between persons 60-69 years 
old to 200-700 per 100.000 in persons over age 80.  
5. There are differences amongst cultural, demographic and ethnic variability in incidence 
and prevalence studies. 
6. Sex patterns remain unclear for prevalence and incidence.  
7. Dementia risk can increase two- to four-fold among individuals who have at least one 
first degree relative with dementia. 
8. Hypertension, histories of diabetes, metabolic syndrome, hyperlipidemia, myocardial 
infarction/cardiac decomposition, heavy smoking, obesity and a history of stroke are 
other risk factors for VaD. 
9. Finally, about epidemiology of VaD is not clear as well as AD. We need more studies in 
the world.  
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